European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen.…
![Manténgase en [u]contacto[/u]](/paper-plane.svg)
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label…
Meet the centre – Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe.…
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug…
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study,…
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study.…
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European…
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE…
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all…
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during…